Research and development of protelytics from natural sources for the treatment of thrombotic states and chronic wounds (Q11201)

From EU Knowledge Graph
Revision as of 15:41, 22 October 2020 by DG Regio (talk | contribs) (‎Removed claim: summary (P836): The project concerns the development of a procedure for the preparation of highly effective proteolytics (KR-X) from Antarctic Krill, which will be used in the various fields of medicine. In addition to the preparation process, there will be two protypes Proteolytics KR-X — for the treatment of chronic wounds and for the thrombolysis of vascular thrombosis (KR-X). The mechanism of action of the enzyme on unwanted fibrin and fragments is expect...)
Jump to navigation Jump to search
Project in Czech Republic financed by DG Regio
Language Label Description Also known as
English
Research and development of protelytics from natural sources for the treatment of thrombotic states and chronic wounds
Project in Czech Republic financed by DG Regio

    Statements

    country
    Czechia
    0 references
    EU contribution
    5,769,000.0 Czech koruna
    0 references
    230,760.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    budget
    15,384,000.0 Czech koruna
    0 references
    615,360.0 Euro
    exchange rate to Euro
    0.04 Euro
    point in time
    10 January 2020
    0 references
    co-financing rate
    37.5 percent
    0 references
    start time
    12 May 2017
    0 references
    expected end time
    17 April 2020
    0 references
    beneficiary name (string)
    VUAB Pharma a.s.
    0 references
    beneficiary
    VUAB Pharma
    0 references
    coordinate location

    50°9'46.91"N, 14°23'2.26"E
    0 references
    postal code
    25263
    0 references
    summary
    Předmětem projektu je vývoj postupu přípravy vysoce účinných proteolytik (KR-X) z antarktického krillu, které budou použity v různých oborech medicíny. Výstupem, kromě technologických postupů přípravy, budou dva prototypy proteolytika KR-X - pro léčbu chronických ran a pro trombolýzu cévních trombů. Díky mechanismu působení enzymu na nežádoucí fibrin a fragmenty se předpokládá u pacientů lepší snášenlivost a nižší bolestivost léčby oproti agresívnějším enzymatickým prostředkům. a. (Czech)
    0 references

    Identifiers

    Czech Kohesio ID
    CZ.01.1.02/0.0/0.0/16_083/0010108
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q11201&oldid=6600362"